ARQT — Arcutis Biotherapeutics, Inc. stock price, charts and financials

Latest market price

25.70

+0.41+1.62%

Overview Short InterestFilings

ARQTQT67Arcutis Biotherapeutics, Inc.·NASDAQ

Overview Short InterestFilings

25.70+1.62%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE-0.67%$46.11 MBX-2.76%$65.95 NAMS-0.05%$27.95 GPCR-1.00%$52.61 GRAL+7.61%$74.77 IRON+0.20%$77.59 TNGX+0.61%$27.24 ALMS-1.30%$27.24

Snapshot

Index	-	P/E	114.54	EPS (ttm)	0.22	Insider Own	18.07%	Shs Outstand	125.08M	Perf Week	-5.85%

Market Cap	3.16B	Forward P/E	21.17	EPS next Y	1.19	Insider Trans	-0.72%	Shs Float	110.19M	Perf Month	-12.13%

Enterprise Value	3.24B	PEG	0.02	EPS next Q	-	Inst Own	-	Short Float	12.31%	Perf Quarter	22.41%

Income	27.20M	P/S	6.82	EPS this Y	1355.80%	Inst Trans	-	Short Ratio	7.70	Perf Half Y	-2.99%

Sales	463.98M	P/B	14.96	EPS next Y	217.16%	ROA	5.84%	Short Interest	13.56M	Perf YTD	-12.91%

Book/sh	-	P/C	79.45	EPS next 5Y	67.14%	ROE	15.05%	52W High	32.29 -20.40%	Perf Year	64.65%

Cash/sh	-	P/FCF	76.43	EPS past 3/5Y	-	ROIC	9.95%	52W Low	13.92 84.60%	Perf 3Y	146.73%

Dividend Est.	-	EV/EBITDA	73.50	Sales past 3/5Y	354.68% -	Gross Margin	91.14%	Volatility	5.60% 4.47%	Perf 5Y	8.40%

Dividend TTM	-	EV/Sales	6.99	EPS Y/Y TTM	97.41%	Oper. Margin	7.38%	ATR (14)	1.27	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.67	Sales Y/Y TTM	111.17%	Profit Margin	6.15%	RSI (14)	41.04	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	2.92	EPS Q/Q	55.00%	SMA20	-7.37%	Beta	1.46	Target Price	36.67

Payout	0.00%	Debt/Eq	0.52	Sales Q/Q	59.09%	SMA50	-2.23%	Rel Volume	1.36	Prev Close	25.29

Employees	354	LT Debt/Eq	0.03	Earnings	Oct 27	SMA200	-0.58%	Avg Volume	1.80M	Price	25.70

IPO Date	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-39.91% 1.66%	Net Debt/EBITDA	1.81	Volume	2,448,164	Change	1.62%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-06-26	Reiterated	Morgan Stanley	Overweight	$34 → $38
Aug-06-26	Reiterated	Guggenheim	Buy	$38
Feb-26-26	Reiterated	HC Wainwright & Co.	Buy	$30 → $34
Nov-28-25	Reiterated	Mizuho	Outperform	$32 → $37
Oct-30-25	Reiterated	Goldman Sachs	Neutral	$37 → $29
Oct-29-25	Reiterated	H.C. Wainwright	Buy	$22 → $30
Oct-29-25	Reiterated	Mizuho Securities	Outperform	$18 → $32
Mar-11-25	Reiterated	Jefferies	Buy	$19
Dec-30-24	Initiated	H.C	Buy	$19
May-15-24	Reiterated	Needham	Buy	$18

Latest News

Aug-07-26

Aug-07-2604:00PM

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Aug-06-26

Aug-06-2601:19PM

Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38Benzinga

08:30AM

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitabilityfool.com

Aug-05-26

Aug-05-2610:00PM

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcriptseekingalpha.com

06:11PM

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimateszacks.com

06:05PM

Arcutis Biotherapeutics Q2 Earnings Call Highlightsmarketbeat.com

04:00PM

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com

Aug-03-26

Aug-03-2611:35AM

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimateszacks.com

Jul-29-26

Jul-29-2611:06AM

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Releasezacks.com

Jul-23-26

Jul-23-2611:00AM

Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout SetupChartMill

Jul-21-26

Jul-21-2610:55AM

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Betzacks.com

Jul-17-26

Jul-17-2610:10AM

Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical SetupChartMill

Jul-16-26

Jul-16-2609:00AM

Arcutis Expands Board of Directors with Appointment of Chris Peetzglobenewswire.com

Jul-15-26

Jul-15-2604:00PM

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026globenewswire.com

Jul-09-26

Jul-09-2601:37PM

Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatmentinvestors.com

Company

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	464	376	197	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	42	37	19	—	—	—	—	—	—
Gross Profit	424	339	177	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	297	275	229	—	—	—	—	—	—
Research and Development	91	77	76	—	—	—	—	—	—
Other Operating Expense	0	0	1	—	—	—	—	—	—
Operating Income	34	-12	-128	—	—	—	—	—	—
Interest Expense	13	12	27	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	8	9	16	—	—	—	—	—	—
Net Income Before Taxes	29	-15	-139	—	—	—	—	—	—
Income Taxes	0	1	1	—	—	—	—	—	—
Consolidated Net Income	28	-16	-140	—	—	—	—	—	—
Net Income From Continuing Operations	28	-16	-140	—	—	—	—	—	—
Net Income	28	-16	-140	—	—	—	—	—	—
EPS (Recurring)	0.22	-0.13	-1.16	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.22	-0.13	-1.16	—	—	—	—	—	—
EPS (Diluted)	0.21	-0.13	-1.16	—	—	—	—	—	—
EBITDA	44	2	-110	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	122.38	—	—	—	—	—	—	—	—
Price To Sales Ratio	7.26	9.81	8.56	—	—	—	—	—	—
Gross Margin	91.38	90.16	89.85	—	—	—	—	—	—
Operating Margin	7.33	-3.19	-64.97	—	—	—	—	—	—
Net Margin	6.03	-4.26	-71.07	—	—	—	—	—	—
Shares Outstanding	131	127	121	—	—	—	—	—	—
Market Capitalization	3,367	3,688	1,686	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Matsuda Masaru	See Remarks	Aug 03 '26	Sale	26.12	1,230	32,124	126,171	Aug 05
Burnett Patrick	See Remarks	Aug 03 '26	Sale	26.12	955	24,942	119,289	Aug 05
Watanabe Todd	See Remarks	Aug 03 '26	Sale	26.12	4,375	114,261	717,203	Aug 05
Welgus Howard G.	Director	Jul 15 '26	Option Exercise	7.93	4,096	32,475	41,839	Jul 17
Welgus Howard G.	Director	Jul 15 '26	Sale	26.91	4,730	127,284	37,109	Jul 17
Welgus Howard G.	Director	Jun 17 '26	Sale	25.67	635	16,300	37,743	Jun 17
LIN SUE-JEAN	Director	Jun 15 '26	Sale	24.38	4,946	120,587	27,567	Jun 17
Welgus Howard G.	Director	Jun 15 '26	Option Exercise	7.93	4,096	32,475	42,474	Jun 17
Welgus Howard G.	Director	Jun 15 '26	Sale	24.41	4,096	99,980	38,378	Jun 17
Vairavan Latha	SVP Chief Financial Officer	May 11 '26	Sale	21.05	435	9,157	85,978	May 13
Burnett Patrick	See Remarks	May 11 '26	Sale	21.05	222	4,673	120,244	May 13
Matsuda Masaru	See Remarks	May 04 '26	Sale	23.31	8,256	192,415	126,689	May 06
Burnett Patrick	See Remarks	May 04 '26	Sale	23.61	684	16,150	120,466	May 06
Vairavan Latha	SVP Chief Financial Officer	May 04 '26	Sale	23.61	1,341	31,662	86,413	May 06
Watanabe Todd	See Remarks	May 04 '26	Sale	23.61	3,172	74,893	720,755	May 06

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.